BlackRock
PBLS

BlackRock’s Parabilis Medicines Inc PBLS Stock Holding History

BlackRock’s Portfolio PBLS Stock Details PBLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$90.1M Buy
+2,790,665
New +$97.4M ﹤0.01% 2257

Other funds holding PBLS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Alphabet Inc
Alphabet Inc Mountain View, California $88.3B AUM 46.07% 1-Year Est. Return
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals Tarrytown, New York $180M AUM 18.92% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
General Atlantic
General Atlantic New York $2.48B AUM 19.88% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

BlackRock's PBLS Position: Q3 2026 in Review

BlackRock opened a new position in Parabilis Medicines Inc (PBLS) in Q3 2026: 2,790,665 shares worth $90.1M. The stake represents ﹤0.01% of the portfolio and ranks #2257 among its holdings.

79 funds tracked by Wall St. Rank hold PBLS as of Q3 2026.

  • BlackRock held 2,790,665 shares of Parabilis Medicines Inc worth $90.1M as of Q3 2026.
  • Parabilis Medicines Inc was a new BlackRock position in Q3 2026.
  • Parabilis Medicines Inc made up ﹤0.01% of BlackRock's portfolio in Q3 2026, its #2257 holding.
  • 79 funds tracked by Wall St. Rank held Parabilis Medicines Inc as of Q3 2026.

Based on BlackRock's 13F filing for Q3 2026, filed 13 Nov 2026.